Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 439
Filter
1.
Am J Hematol ; 98 Suppl 4: S74-S81, 2023 05.
Article in English | MEDLINE | ID: mdl-36999459

ABSTRACT

COVID-19 is a complex disease manifesting in a broad severity spectrum and involving distinct organs and systems. Hyperinflammation, including complement over-activation, has a pivotal role in severe COVID-19 pathobiology, stimulating the inflammatory response, causing microangiopathy, platelet-neutrophil activation, and hypercoagulability. SARS-CoV-2 can directly activate the complement system by the classic, alternative, and lectin pathways, and infected cells can produce intracellular complement (the complesome). COVID-19 severity appears to be associated with the degree of complement activation, and it has been hypothesized that patients with COVID-19 may benefit from therapeutic complement inhibition. Different complement cascade molecules may be targeted with potential advantages and disadvantages. Which target(s) is the most effective and when is the best timing for intervention remain open questions. Early phase I and phase II clinical trials have shown promising but conflicting results, warranting phase III controlled randomized trials. Upstream complement inhibition appears to better and more effectively block hyperinflammation with potential clinical significance. Understanding how SARS-CoV-2 exploits the complement system can add precious information about the pathogenesis of other infections, inflammatory, and autoimmune diseases beyond COVID-19.


Subject(s)
COVID-19 , Humans , COVID-19/complications , SARS-CoV-2 , Inflammation/metabolism , Complement Activation , Neutrophils , Complement System Proteins/metabolism , Complement System Proteins/pharmacology
2.
Parasit Vectors ; 14(1): 451, 2021 Sep 06.
Article in English | MEDLINE | ID: mdl-34488849

ABSTRACT

Complement has been considered as an important factor impacting the host-pathogen association of spirochetes belonging to the Borrelia burgdorferi sensu lato complex, and may play a role in the spirochete's ecology. Birds are known to be important hosts for ticks and in the maintenance of borreliae. Recent field surveys and laboratory transmission studies indicated that certain avian species act as reservoir hosts for different Borrelia species. Nevertheless, our current understanding of the molecular mechanisms determining host tropism of Borrelia is still in its fledgling stage. Concerning the role of complement in avian-host tropism, only a few bird species and Borrelia species have been analysed so far. Here, we performed in vitro serum bactericidal assays with serum samples collected from four bird species including the European robin Erithacus rubecula, the great tit Parus major, the Eurasian blackbird Turdus merula, and the racing pigeon Columba livia, as well as four Borrelia species (B. afzelii, B. garinii, B. valaisiana, and B. burgdorferi sensu stricto). From July to September 2019, juvenile wild birds were caught using mist nets in Portugal. Racing pigeons were sampled in a loft in October 2019. Independent of the bird species analysed, all Borrelia species displayed an intermediate serum-resistant or serum-resistant phenotype except for B. afzelii challenged with serum from blackbirds. This genospecies was efficiently killed by avian complement, suggesting that blackbirds served as dead-end hosts for B. afzelii. In summary, these findings suggest that complement contributes in the avian-spirochete-tick infection cycle and in Borrelia-host tropism.


Subject(s)
Birds/blood , Birds/microbiology , Borrelia/drug effects , Complement System Proteins/pharmacology , Disease Reservoirs/veterinary , Animals , Animals, Wild , Bird Diseases/microbiology , Birds/classification , Borrelia/classification , Borrelia/physiology , Disease Reservoirs/microbiology , Host Microbial Interactions , Lyme Disease/transmission , Portugal
3.
Nat Microbiol ; 6(2): 157-161, 2021 02.
Article in English | MEDLINE | ID: mdl-33432151

ABSTRACT

We characterized two bacteriophages, ΦFG02 and ΦCO01, against clinical isolates of Acinetobacter baumannii and established that the bacterial capsule is the receptor for these phages. Phage-resistant mutants harboured loss-of-function mutations in genes responsible for capsule biosynthesis, resulting in capsule loss and disruption of phage adsorption. The phage-resistant strains were resensitized to human complement, beta-lactam antibiotics and alternative phages and exhibited diminished fitness in vivo. Using a mouse model of A. baumannii infection, we showed that phage therapy was effective.


Subject(s)
Acinetobacter Infections/microbiology , Acinetobacter Infections/therapy , Acinetobacter baumannii/virology , Anti-Bacterial Agents/pharmacology , Bacteriophages/physiology , Phage Therapy , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/genetics , Animals , Bacterial Capsules/virology , Complement System Proteins/pharmacology , Disease Models, Animal , Drug Resistance, Bacterial , Female , Humans , Loss of Function Mutation , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , beta-Lactamase Inhibitors/pharmacology
4.
Genes (Basel) ; 13(1)2021 12 29.
Article in English | MEDLINE | ID: mdl-35052426

ABSTRACT

Unlike microbes that infect the human body, cancer cells are descended from normal cells and are not easily recognizable as "foreign" by the immune system of the host. However, if the malignant cells can be specifically earmarked for attack by a synthetic "designator", the powerful effector mechanisms of the immune response can be conscripted to treat cancer. To implement this strategy, we have been developing aptamer-derived molecular adaptors to invoke synthetic immune responses against cancer cells. Here we describe multi-valent aptamers that simultaneously bind target molecules on the surface of cancer cells and an activated complement protein, which would tag the target molecules and their associated cells as "foreign" and trigger multiple effector mechanisms. Increased deposition of the complement proteins on the surface of cancer cells via aptamer binding to membrane targets could induce the formation of the membrane attack complex or cytotoxic degranulation by phagocytes and natural killer cells, thereby causing irreversible destruction of the targeted cells. Specifically, we designed and constructed a bi-functional aptamer linking EGFR and C3b/iC3b, and used it in a cell-based assay to cause lysis of MDA-MB-231 and BT-20 breast cancer cells, with either human or mouse serum as the source of complement factors.


Subject(s)
Antineoplastic Agents/pharmacology , Aptamers, Nucleotide/pharmacology , Breast Neoplasms/therapy , Complement System Proteins/pharmacology , Killer Cells, Natural/immunology , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Cell Death , Female , Humans , Killer Cells, Natural/drug effects , Phagocytosis , Tumor Cells, Cultured
5.
Microbiology (Reading) ; 166(7): 629-640, 2020 07.
Article in English | MEDLINE | ID: mdl-32421492

ABSTRACT

The atypical bacterial pathogen Mycoplasma pneumoniae is a leading etiological agent of community-acquired pneumonia in humans; infections are often recalcitrant, recurrent and resistant to antibiotic treatment. These characteristics suggest a mechanism that facilitates long-term colonization in hosts. In an in vitro setting, M. pneumoniae forms biofilms that are unusual in that motility plays no more than a very limited role in their formation and development. Given the unusual nature of M. pneumoniae biofilms, open questions remain concerning phenotypes associated with persistence, such as what properties might favour the bacteria while minimizing host damage. M. pneumoniae also produces several cytotoxic molecules including community-acquired respiratory distress syndrome (CARDS) toxin, H2S and H2O2, but how it deploys these agents during growth is unknown. Whereas several biochemical techniques for biofilm disruption were ineffective, sonication was required for disruption of M. pneumoniae biofilms to generate individual cells for comparative studies, suggesting unusual physical properties likely related to the atypical cell envelope. Nonetheless, like for other bacteria, biofilms were less susceptible to antibiotic inhibition and complement killing than dispersed cells, with resistance increasing as the biofilms matured. CARDS toxin levels and enzymatic activities associated with H2S and H2O2 production were highest during early biofilm formation and decreased over time, suggesting attenuation of virulence in connection with chronic infection. Collectively, these findings result in a model of how M. pneumoniae biofilms contribute to both the establishment and propagation of M. pneumoniae infections, and how both biofilm towers and individual cells participate in persistence and chronic disease.


Subject(s)
Bacterial Proteins/metabolism , Bacterial Toxins/metabolism , Biofilms/drug effects , Biofilms/growth & development , Hydrogen Peroxide/metabolism , Mycoplasma pneumoniae/drug effects , Mycoplasma pneumoniae/physiology , Sulfites/metabolism , Animals , Anti-Bacterial Agents/pharmacology , Complement System Proteins/pharmacology , Drug Resistance, Fungal , Guinea Pigs , Humans , Microbial Viability , Pneumococcal Infections/microbiology , Virulence
6.
J Immunol ; 204(12): 3283-3295, 2020 06 15.
Article in English | MEDLINE | ID: mdl-32434942

ABSTRACT

Neisseria gonorrhoeae deploys a unique immune evasion strategy wherein the lacto-N-neotetraose termini of lipooligosaccharide (LOS) are "capped" by a surface LOS sialyltransferase (Lst), using extracellular host-derived CMP-sialic acid (CMP-Neu5Ac in humans). LOS sialylation enhances complement resistance by recruiting factor H (FH; alternative complement pathway inhibitor) and also by limiting classical pathway activation. Sialylated LOS also engages inhibitory Siglecs on host leukocytes, dampening innate immunity. Previously, we showed that analogues of CMP-sialic acids (CMP-nonulosonates [CMP-NulOs]), such as CMP-Leg5,7Ac2 and CMP-Neu5Ac9N3, are also substrates for Lst. Incorporation of Leg5,7Ac2 and Neu5Ac9N3 into LOS results in N. gonorrhoeae being fully serum sensitive. Importantly, intravaginal administration of CMP-Leg5,7Ac2 attenuated N. gonorrhoeae colonization of mouse vaginas. In this study, we characterize and develop additional candidate therapeutic CMP-NulOs. CMP-ketodeoxynonulosonate (CMP-Kdn) and CMP-Kdn7N3, but not CMP-Neu4,5Ac2, were substrates for Lst, further elucidating gonococcal Lst specificity. Lacto-N-neotetraose LOS capped with Kdn and Kdn7N3 bound FH to levels ∼60% of that seen with Neu5Ac and enabled gonococci to resist low (3.3%) but not higher (10%) concentrations of human complement. CMP-Kdn, CMP-Neu5Ac9N3, and CMP-Leg5,7Ac2 administered intravaginally (10 µg/d) to N. gonorrhoeae-colonized mice were equally efficacious. Of the three CMP-NulOs above, CMP-Leg5,7Ac2 was the most pH and temperature stable. In addition, Leg5,7Ac2-fed human cells did not display this NulO on their surface. Moreover, CMP-Leg5,7Ac2 was efficacious against several multidrug-resistant gonococci in mice with a humanized sialome (Cmah-/- mice) or humanized complement system (FH/C4b-binding protein transgenic mice). CMP-Leg5,7Ac2 and CMP-Kdn remain viable leads as topical preventive/therapeutic agents against the global threat of multidrug-resistant N. gonorrhoeae.


Subject(s)
Cytidine Monophosphate N-Acetylneuraminic Acid/pharmacology , Cytidine Monophosphate/analogs & derivatives , Cytidine Monophosphate/physiology , Drug Resistance, Multiple, Bacterial/drug effects , Gonorrhea/drug therapy , Neisseria gonorrhoeae/drug effects , Neuraminic Acids/pharmacology , Sialic Acids/pharmacology , Animals , Cell Line, Tumor , Complement Factor H/metabolism , Complement System Proteins/pharmacology , Cytidine Monophosphate/pharmacology , Female , Gonorrhea/metabolism , Gonorrhea/microbiology , Humans , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred BALB C , Mice, Transgenic , Oligosaccharides/physiology , Sialyltransferases/pharmacology
7.
Int J Mol Sci ; 20(22)2019 Nov 08.
Article in English | MEDLINE | ID: mdl-31717311

ABSTRACT

The virulence of bacterial outer membrane vesicles (OMVs) contributes to innate microbial defense. Limited data report their role in interspecies reactions. There are no data about the relevance of OMVs in bacterial-yeast communication. We hypothesized that model Moraxella catarrhalis OMVs may orchestrate the susceptibility of pathogenic bacteria and yeasts to cationic peptides (polymyxin B) and serum complement. Using growth kinetic curve and time-kill assay we found that OMVs protect Candida albicans against polymyxin B-dependent fungicidal action in combination with fluconazole. We showed that OMVs preserve the virulent filamentous phenotype of yeasts in the presence of both antifungal drugs. We demonstrated that bacteria including Haemophilus influenza, Acinetobacter baumannii, and Pseudomonas aeruginosa coincubated with OMVs are protected against membrane targeting agents. The high susceptibility of OMV-associated bacteria to polymyxin B excluded the direct way of protection, suggesting rather the fusion mechanisms. High-performance liquid chromatography-ultraviolet spectroscopy (HPLC-UV) and zeta-potential measurement revealed a high sequestration capacity (up to 95%) of OMVs against model cationic peptide accompanied by an increase in surface electrical charge. We presented the first experimental evidence that bacterial OMVs by sequestering of cationic peptides may protect pathogenic yeast against combined action of antifungal drugs. Our findings identify OMVs as important inter-kingdom players.


Subject(s)
Bacteria/pathogenicity , Cell Membrane/metabolism , Complement System Proteins/pharmacology , Extracellular Vesicles/metabolism , Peptides/pharmacology , Serum/metabolism , Yeasts/pathogenicity , Bacteria/drug effects , Bacteria/growth & development , Cations , Cell Membrane/drug effects , Cell Membrane/ultrastructure , Cell Membrane Permeability/drug effects , Extracellular Vesicles/drug effects , Extracellular Vesicles/ultrastructure , Fluconazole/pharmacology , Humans , Microbial Sensitivity Tests , Microbial Viability/drug effects , Moraxella/metabolism , Polymyxin B/pharmacology , Static Electricity , Virulence/drug effects , Yeasts/drug effects , Yeasts/growth & development
8.
J Infect Dis ; 219(9): 1439-1447, 2019 04 16.
Article in English | MEDLINE | ID: mdl-30476337

ABSTRACT

Emergence of multidrug-resistant (MDR) bacterial infections is a major problem in clinical medicine. Development of new strategies such as phage therapy may be a novel approach for treatment of life-threatening infections caused by MDR bacteria. A newly isolated phage, MMI-Ps1, with strong lytic activity was used for treatment of acute lung infection with Pseudomonas aeruginosa in a mouse model. Intranasal administration of a single dose of MMI-Ps1 immediately after infection provided a significant level of protection and increased the survival duration. Moreover, treatment of infected mice with phage as late as 12 hours after infection was still protective. Our in vitro results are the first to show the synergistic elimination of serum-resistant Pseudomonas strains by phage and complement. Phage therapy increases the efficacy of complement-mediated lysis of serum-resistant P. aeruginosa strains, indicating the importance of an intact complement system in clearing Pseudomonas infection during phage therapy.


Subject(s)
Bacteriophages , Complement System Proteins/therapeutic use , Lung Diseases/microbiology , Lung Diseases/therapy , Phage Therapy , Pseudomonas Infections/therapy , Acute Disease , Administration, Intranasal , Animals , Bacteriolysis/drug effects , Caudovirales , Colony Count, Microbial , Complement System Proteins/pharmacology , Disease Models, Animal , Drug Resistance, Multiple, Bacterial , Female , In Vitro Techniques , Lung Diseases/prevention & control , Mice , Mice, Inbred BALB C , Pseudomonas Infections/microbiology , Pseudomonas Infections/prevention & control , Pseudomonas aeruginosa/physiology
9.
J Immunol ; 200(12): 4094-4101, 2018 06 15.
Article in English | MEDLINE | ID: mdl-29695418

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a painful and debilitating side effect of cancer chemotherapy with an unclear pathogenesis. Consequently, the available therapies for this neuropathic pain syndrome are inadequate, leading to a significantly reduced quality of life in many patients. Complement, a key component of the innate immune system, has been associated with neuroinflammation, a potentially important trigger of some types of neuropathic pain. However, the role of complement in CIPN remains unclear. To address this issue, we developed a C3 knockout (KO) rat model and induced CIPN in these KO rats and wild-type littermates via the i.p. administration of paclitaxel, a chemotherapeutic agent associated with CIPN. We then compared the severity of mechanical allodynia, complement activation, and intradermal nerve fiber loss between the groups. We found that 1) i.p. paclitaxel administration activated complement in wild-type rats, 2) paclitaxel-induced mechanical allodynia was significantly reduced in C3 KO rats, and 3) the paclitaxel-induced loss of intradermal nerve fibers was markedly attenuated in C3 KO rats. In in vitro studies, we found that paclitaxel-treated rat neuronal cells activated complement, leading to cellular injury. Our findings demonstrate a previously unknown but pivotal role of complement in CIPN and suggest that complement may be a new target for the development of novel therapeutics to manage this painful disease.


Subject(s)
Complement System Proteins/immunology , Complement System Proteins/pharmacology , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/immunology , Animals , Disease Models, Animal , Hyperalgesia/chemically induced , Hyperalgesia/immunology , Immunity, Innate/drug effects , Immunity, Innate/immunology , Nerve Fibers/drug effects , Nerve Fibers/immunology , Neuralgia/chemically induced , Neuralgia/immunology , Paclitaxel , Quality of Life , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley
10.
Ophthalmologica ; 239(4): 215-224, 2018.
Article in English | MEDLINE | ID: mdl-29486466

ABSTRACT

BACKGROUND: Retinal pigment epithelial (RPE) cells undergo functional changes upon complement stimulation, which play a role in the pathogenesis of age-related macular degeneration (AMD). These effects are in part enhanced by pretreating ARPE-19 cells with UV-irradiated photoreceptor outer segments (UV-POS) in vitro. The aim of this study was to investigate the effects of human complement serum (HCS) treatment on p44/42 mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2 [ERK1/2]) activation in ARPE-19 cells pretreated with UV-POS. METHODS: UV-POS-pretreated ARPE-19 cells were stimulated with 5% HCS or heat-inactivated HCS (HI-HCS) as a control. Pro tein expression of phosphorylated (activated) ERK1/2, total ERK1/2, Bax, and Bcl-2 was analyzed by Western blotting. Cell culture supernatants were analyzed for IL-6, IL-8, MCP-1, and VEGF by enzyme-linked immunosorbent assay (ELISA). Furthermore, extra- and intracellular reactive oxygen species (ROS) were determined. RESULTS: The amount of phosphorylated ERK1/2 was increased in UV-POS-pretreated ARPE-19 cells, especially in combination with HCS stimulation, compared to non-pretreated ARPE-19 cells incubated with HCS alone or HI-HCS. The same observation was made for Bax and Bcl-2 expression. Furthermore, an increase in extra- and intracellular ROS was detected in UV-POS-pretreated ARPE-19 cells. The ELISA data showed that the production of IL-6, IL-8, and MCP-1 tended to increase in response to HCS in both UV-POS-pretreated and non-pretreated ARPE-19 cells. CONCLUSIONS: Our data imply that ERK1/2 activation in ARPE-19 cells may represent a response mechanism to cellular and oxidative stress, associated with apoptosis-regulating factors such as Bax and Bcl-2, which might play a role in AMD, while ERK1/2 seems not to represent the crucial signaling pathway mediating the functional changes in RPE cells in response to complement stimulation.


Subject(s)
Complement System Proteins/pharmacology , MAP Kinase Signaling System/genetics , Macular Degeneration/genetics , Oxidative Stress , Reactive Oxygen Species/metabolism , Retinal Pigment Epithelium/metabolism , Animals , Blotting, Western , Cells, Cultured , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Humans , Macular Degeneration/metabolism , Macular Degeneration/pathology , Retinal Pigment Epithelium/pathology , Swine , Ultraviolet Rays/adverse effects
11.
Article in English | MEDLINE | ID: mdl-28504094

ABSTRACT

Antimicrobial substances in serum include circulating complement proteins and acute phase proteins (APPs). We identified gene sequences for APPs, haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA) in marsupial genomes. Hp and SAA levels were measured in red-tailed phascogale (Phascogale calura) sera using commercially available assays. Hp levels were higher in males than females, while SAA levels suggest the phascogales used in this study were healthy. Serum was co-cultured with four bacterial species. Bacterial growth was inhibited after incubation at 37°C, however effectiveness differed with bacteria and incubation time. The least amount of bacterial growth was noticed after introduction to K. pneumoniae, and most when introduced to P. aeruginosa. Despite marsupials not having mature immune tissues at birth, and unable to mount specific immune responses, this study suggests other immune strategies, such as APPs in serum likely aid marsupials in their defence against pathogens.


Subject(s)
Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Blood Bactericidal Activity , Complement System Proteins/pharmacology , Acute-Phase Proteins/analysis , Acute-Phase Proteins/genetics , Acute-Phase Proteins/pharmacology , Animals , Bacteria/growth & development , C-Reactive Protein/analysis , Haptoglobins/analysis , Haptoglobins/pharmacology , Klebsiella pneumoniae/drug effects , Marsupialia , Pseudomonas aeruginosa/drug effects , Serum/chemistry , Serum Amyloid A Protein/analysis
12.
Redox Biol ; 12: 571-581, 2017 08.
Article in English | MEDLINE | ID: mdl-28390315

ABSTRACT

Antioxidant glutathione (GSH) plays an important role in the regulation of immunity. However, little is known about its effects on humoral immunity, especially its action on effector molecules like antibody and complement. Given that these molecules contain abundant disulfide bonds, we speculated that GSH might influence the action of these proteins via its thiol function. Using a model of a glomerular mesangial cell (MC) lysis induced by antibodies plus complement, we addressed this hypothesis. Exposure of rat MCs to anti-Thy-1 antibody plus complement or anti-MC rabbit serum caused a complement-dependent cell lysis, which was completely blocked by GSH. Moreover, GSH potently prevented the antibody-mediated agglutination of red blood cells and aggregation of antibody-sensitized microspheres. Further analysis revealed that GSH inhibited antibody binding to antigens and promoted the conversion of the antibodies to its reduced forms. GSH also potently inhibited the formation and deposition of C5b-9 in MCs and suppressed both the classic and alternative complement activation pathway. Lastly, GSH attenuated P38 activation, an oxidative sensitive kinase that partially mediated the antibody- and complement-dependent MC lysis. Depletion of GSH via inhibiting gamma-glutamylcysteine synthetase or xCT transporter augmented P38 activation and sensitized MCs to the cell lysis. Collectively, our results indicate that GSH protects cells from immunological cell damage via mechanisms involving inhibition of antibody binding to the antigens, suppression of complement activation and augmentation of cellular defense mechanism. Our study provides novel mechanistic insights into the actions of GSH in the regulation of immune responses and suggests that GSH might be used to treat certain immune disorders.


Subject(s)
Complement System Proteins/pharmacology , Glutathione/pharmacology , Isoantibodies/pharmacology , Mesangial Cells/drug effects , Animals , Cells, Cultured , Complement Activation , Complement Membrane Attack Complex/pharmacology , MAP Kinase Signaling System/drug effects , Mesangial Cells/immunology , Mesangial Cells/metabolism , Protein Binding/drug effects , Rabbits , Rats
13.
Nanotoxicology ; 11(3): 382-394, 2017 04.
Article in English | MEDLINE | ID: mdl-28287003

ABSTRACT

The complement system is a key humoral component of innate immunity, serving as the first line of defense against intruders, including foreign synthetic nanomaterials. Although gold nanomaterials (AuNMs) are widely used in nanomedicine, their immunological response is not well understood. Using AuNMs of three shapes commonly used in biomedical applications: spherical gold nanoparticles, gold nanostars and gold nanorods, we demonstrated that AuNMs activated whole complement system, leading to the formation of SC5b-9 complex. All three complement pathways were simultaneously activated by all the AuNMs. Recognition molecules of the complement system interacted with all AuNMs in vitro, except for l-ficolin, but the correlation between these interactions and corresponding complement pathway activation was only observed in the classical and alternative pathways. We also observed the mediating role of complement activation in cellular uptake of all AuNMs by human U937 promonocytic cells, which expresses complement receptors. Taken together, our results highlighted the potential immunological challenges for clinical applications of AuNMs that were often overlooked.


Subject(s)
Complement Activation/drug effects , Complement System Proteins/pharmacology , Gold/pharmacology , Nanostructures , Adsorption , Complement C1q/pharmacology , Complement C3b/pharmacology , Humans , Macrophages/metabolism , Nanomedicine , U937 Cells
14.
Int J Hematol ; 105(2): 118-128, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27826715

ABSTRACT

Hematopoietic stem cells are a remarkable resource currently used for the life saving treatment, hematopoietic stem cell transplantation. Today, hematopoietic stem cells are primarily obtained from mobilized peripheral blood following treatment of the donor with the cytokine G-CSF, and in some settings, chemotherapy and/or the CXCR4 antagonist plerixafor. The collection of hematopoietic stem cells is contingent on adequate and timely mobilization of these cells into the peripheral blood. The use of healthy donors, particularly when unrelated to the patient, requires mobilization strategies be safe for the donor. While current mobilization strategies are largely successful, adequate mobilization fails to occur in a significant portion of donors. Understanding the mechanisms involved in the egress of stem cells from the bone marrow provides opportunities to further improve the process of collecting hematopoietic stem cells. Here, the role extracellular components of the blood and bone marrow in the mobilization process are discussed.


Subject(s)
Hematopoietic Stem Cell Mobilization/methods , Animals , Chemokines/chemistry , Chemokines/pharmacology , Complement System Proteins/pharmacology , Extracellular Matrix/chemistry , Humans , Stem Cell Niche
15.
J Exp Zool A Ecol Integr Physiol ; 327(6): 351-357, 2017 07.
Article in English | MEDLINE | ID: mdl-29356464

ABSTRACT

Complement-an immune protein cascade involved in pathogen lysis-was discovered as a temperature-labile component of vertebrate plasma, yet since that time the thermal performance of complement has not received much attention from a comparative or ecological perspective. We investigated two thermal hypotheses involving the complement system of the cottonmouth snake (Agkistrodon piscivorus). We tested whether complement performance would conform to optimal thermal reaction norms commonly observed in ectotherm ecophysiological studies, predicting that complement efficiency would be maximal at or near the cottonmouth's field body temperatures. We also tested thermal acclimatization of complement performance, by comparing temperature/performance curves from samples collected in three different seasons. Complement efficiency exhibited the same significant positive correlation with temperature in all three seasons. This seasonally invariable temperature-performance relationship may allow easy acquisition of behavioral fever, as well as trade-offs between immune performance and energy balance, ultimately endowing snakes with immunological flexibility not available to endotherms.


Subject(s)
Agkistrodon/immunology , Complement System Proteins/chemistry , Complement System Proteins/pharmacology , Hot Temperature , Immunity, Innate , Animals , Seasons
16.
Invest Ophthalmol Vis Sci ; 57(14): 5910-5918, 2016 Nov 01.
Article in English | MEDLINE | ID: mdl-27802521

ABSTRACT

PURPOSE: Age-related macular degeneration (AMD) commonly causes blindness in the elderly. Yet, it is untreatable in the large fraction of all AMD patients that develop the early dry form. Dry AMD is marked by the deposition of membrane attack complex (MAC) on choriocapillaris (CC), which is implicated in CC degeneration and subsequent atrophy of overlying retinal pigment epithelium. Since MAC is also found on the CC of young eyes, here we investigated whether and how aging increases choroidal endothelial susceptibility to MAC injury. METHODS: Monkey chorioretinal endothelial cells (ECs, RF/6A) were cultured to high passages (>P60) to achieve replicative senescence. We treated ECs with complement-competent human serum to promote MAC deposition and injury, which were assessed by flow cytometry and trypan blue exclusion assay, respectively. Stiffness of EC was measured by atomic force microscopy indentation while Rho GTPase activity was quantified by Rho G-LISA assay. RESULTS: Our findings reveal that senescent ECs are significantly stiffer than their normal counterparts, which correlates with higher cytoskeletal Rho activity in these cells and their greater susceptibility to complement (MAC) injury. Importantly, inhibition of Rho activity in senescent ECs significantly reduced cell stiffness and MAC-induced lysis. CONCLUSIONS: By revealing an important role of senescence-associated choroidal EC stiffening in complement injury, these findings implicate CC stiffening as an important determinant of age-related CC atrophy seen in dry AMD. Future studies are needed to validate these findings in appropriate animal models so new therapeutic targets can be identified for treatment of dry AMD.


Subject(s)
Cellular Senescence/physiology , Choroid/drug effects , Complement Membrane Attack Complex/physiology , Complement System Proteins/pharmacology , Endothelial Cells/drug effects , Macular Degeneration/pathology , Macular Degeneration/physiopathology , Aged , Animals , Cells, Cultured , Choroid/cytology , Choroid/physiology , Complement Membrane Attack Complex/metabolism , Endothelial Cells/physiology , Haplorhini , Humans , Male , Microscopy, Atomic Force , Retina/cytology
17.
Bull Exp Biol Med ; 160(6): 775-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27169636

ABSTRACT

Toxicity of human blood serum for ciliate Tetrahymena pyriformis is determined by the complement system. When ciliate are dying after being exposed to blood serum, cell membrane permeability for low-molecular-weight compounds significantly increases, probably due to pore formation. Serine protease inhibitors or exposure to physical factors inducing complement inactivation (e.g., heating up to 56°C) completely prevented ciliate death under the effect of human serum. Activation of serum complement upon interaction with Tetrahymena cells occurred by the classical or lectin pathway, while the contribution of the alternative activation pathway was negligible.


Subject(s)
Antiprotozoal Agents/pharmacology , Complement System Proteins/pharmacology , Tetrahymena pyriformis/physiology , Cell Membrane Permeability/drug effects , Complement Activation , Humans , Serum , Tetrahymena pyriformis/drug effects
18.
Exp Parasitol ; 167: 83-93, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27181585

ABSTRACT

Leishmaniasis is a group of diseases that presents various clinical manifestations. Many studies have shown that the parasite plays an important role in the clinical manifestations and prognosis of this disease. The cutaneous and mucosal forms of American tegumentary leishmaniasis (ATL) are associated with Leishmania (Viannia) braziliensis, which exhibits intraspecific genetic polymorphisms and various clinical manifestations. The present study focused on four different L. braziliensis strains that were isolated from patients with distinct Glucantime(®) treatment responses. The isolates were described based on their molecular, biological, and infective characteristics. Growth patterns in culture medium and different grow phases were analyzed, MID-Logarithimic (Mid-LOG), Logarithimic (LOG) and Stationary (STAT) phases. Complement resistance was evaluated using guinea pig serum. Infection to murine peritoneal macrophages, cytokine and nitric oxide were analyzed. Ultrastructural features were determined by transmission electron microscopy, and molecular characteristics were determined based on random amplified polymorphic DNA (RAPD). All of the L. braziliensis isolates showed typical growth and similar complement sensitivity patterns. Markedly lower infectivity indexes were observed for all strains in the LOG phase, with different cytokine profiles. The ultrastructure analysis revealed distinct differences between the MID-LOG, LOG, and STAT phases. The RAPD results showed a divergence between the isolates of the L. braziliensis. The in vitro characterization of L. braziliensis isolates from humans with different treatment responses using various parameters enabled us to observe differences among the isolates. Molecular and in vivo characterizations are currently under study to improve understanding of the parasite-host interaction that can imply in the clinical manifestation differences.


Subject(s)
Antiprotozoal Agents/therapeutic use , Leishmania braziliensis/physiology , Leishmaniasis, Cutaneous/parasitology , Meglumine/therapeutic use , Organometallic Compounds/therapeutic use , Adult , Aged , Animals , Brazil , Complement System Proteins/pharmacology , Cytokines/metabolism , DNA, Protozoan/chemistry , DNA, Protozoan/isolation & purification , Female , Guinea Pigs , Humans , Leishmania braziliensis/genetics , Leishmania braziliensis/immunology , Leishmania braziliensis/ultrastructure , Leishmaniasis, Cutaneous/drug therapy , Macrophages, Peritoneal/parasitology , Male , Meglumine Antimoniate , Mice , Mice, Inbred BALB C , Microscopy, Electron, Transmission , Middle Aged , Nitric Oxide/metabolism , Random Amplified Polymorphic DNA Technique
19.
J Pharmacol Sci ; 132(4): 224-234, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27103329

ABSTRACT

Suramin inhibits immune responses and protects cells against inflammatory cell injury. However, little is known about its mechanisms. Using an in vitro model of glomerular mesangial cell (MC) lysis induced by antibodies plus complement, we investigated the potential protective effects and mechanisms of suramin on immunologic cell injury. Exposure of rat MCs to anti-Thy-1 antibody plus complement or anti-MC rabbit serum caused complement-dependent cell lysis, which was blocked by suramin and its structural analogue NF023 and NF049, but not by PPADS, an antagonist of purinergic receptors. Addition of exogenous ATP also failed to affect MC lysis. Further analysis revealed that suramin interfered with antibody binding to cell membrane antigens and suppressed antibody-induced phosphorylation of several proteins, including p38. Inhibition of p38 with chemical inhibitor significantly attenuated cell injury. Collectively, our results indicate that suramin protects cells against antibody-initiated and complement-dependent cell injury through inhibition of antibody binding to cell surface antigens and suppression of p38 activation. Our study thus provides novel mechanistic insights into the actions of suramin and suggests that suramin might be used to treat certain immune diseases.


Subject(s)
Antigens, Surface/metabolism , Complement System Proteins/pharmacology , Isoantibodies/pharmacology , Mesangial Cells/drug effects , Suramin/pharmacology , Animals , Antigen-Antibody Reactions/drug effects , Antigen-Antibody Reactions/immunology , Antigens, Surface/immunology , Cell Death/drug effects , Cell Death/immunology , Cells, Cultured , Complement System Proteins/immunology , Immunoglobulins/immunology , Immunoglobulins/metabolism , Isoantibodies/immunology , Mesangial Cells/cytology , Mesangial Cells/immunology , Rabbits , Rats
20.
Vector Borne Zoonotic Dis ; 16(1): 13-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26783940

ABSTRACT

Reaction of vertebrate serum complement with different Borrelia burgdorferi sensu lato species is used as a basis in determining reservoir hosts among domesticated and wild animals. Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii were tested for their sensitivity to sera of exotic vertebrate species housed in five zoos located in the Czech Republic. We confirmed that different Borrelia species have different sensitivity to host serum. We found that tolerance to Borrelia infection possessed by hosts might differ among individuals of the same genera or species and is not affected by host age or sex. Of all zoo animals included in our study, carnivores demonstrated the highest apparent reservoir competency for Lyme borreliosis spirochetes. We showed that selected exotic ungulate species are tolerant to Borrelia infection. For the first time we showed the high tolerance of Siamese crocodile to Borrelia as compared to the other studied reptile species. While exotic vertebrates present a limited risk to the European human population as reservoirs for the causative agents of Lyme borreliosis, cases of incidental spillover infection could lead to successful replication of the pathogens in a new host, changing the status of selected exotic species and their role in pathogen emergence or maintenance. The question if being tolerant to pathogen means to be a competent reservoir host still needs an answer, simply because the majority of exotic animals might never be exposed to spirochetes in their natural environment.


Subject(s)
Borrelia burgdorferi/physiology , Complement System Proteins/pharmacology , Lyme Disease/veterinary , Vertebrates/immunology , Animals , Animals, Zoo , Disease Reservoirs , Female , Lyme Disease/immunology , Lyme Disease/microbiology , Male
SELECTION OF CITATIONS
SEARCH DETAIL